# The Bioequivalence Study of Lamotrigine Dispersible/Chewable Tablets 5mg×5 Compared With Lamotrigine Compressed Tablet 25mg in Chinese Healthy Male Subjects

> **NCT01879423** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 24 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** Lamotrigine Dispersible/Chewable tablets 5mg*5
- **DRUG:** Lamotrigine Compressed tablet 25mg

## Key facts

- **NCT ID:** NCT01879423
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04-28
- **Primary completion:** 2013-06-06
- **Final completion:** 2013-06-06
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01879423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01879423, "The Bioequivalence Study of Lamotrigine Dispersible/Chewable Tablets 5mg×5 Compared With Lamotrigine Compressed Tablet 25mg in Chinese Healthy Male Subjects". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT01879423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*